4.5 Article

Monoamine transporter and receptor interaction profiles of novel psychoactive substances: Para-halogenated amphetamines and pyrovalerone cathinones

期刊

EUROPEAN NEUROPSYCHOPHARMACOLOGY
卷 25, 期 3, 页码 365-376

出版社

ELSEVIER
DOI: 10.1016/j.euroneuro.2014.12.012

关键词

Novel psychoactive substances; Cathinone; Amphetamine; Dopamine; Serotonin; Transporter

资金

  1. Federal Office of Public Health [13.006497]
  2. joint Translational Medicine Hub Innovation Fund of F. Hoffmann-La Roche
  3. University of Basel

向作者/读者索取更多资源

The pharmacology of novel psychoactive substances is mostly unknown. We evaluated the transporter and receptor interaction profiles of a series of para-(4)-substituted amphetamines and pyrovalerone cathinones. We tested the potency of these compounds to inhibit the norepinephrine (NE), dopamine (DA), and serotonin (5-HT) transporters (NET, DAT, and SERT, respectively) using human embryonic kidney 293 cells that express the respective human transporters. We also tested the substance-induced efflux of NE, DA, and 5-HT from monoamine-loaded cells, binding affinities to monoamine receptors, and 5-HT2B receptor activation. Para-(4)-substituted amphetamines, including 4-methylmethcathinone (mephedrone), 4-ethylmethcathinone, 4-fluoroamphetamine, 4-fluoromethamphetamine, 4-fluoromethcatinone (flephedrone), and 4-bromomethcathinone, were relatively more serotonergic (lower DAT:SERT ratio) compared with their analogs amphetamine, methamphetamine, and methcathinone. The 4-methyl, 4-ethyl, and 4-bromo groups resulted in enhanced serotonergic properties compared with the 4-fluoro group. The para-substituted amphetamines released NE and DA. 4-Fluoramphetamine, 4-flouromethamphetamine, 4-methylmethcathinone, and 4-ethylmethcathinone also released 5-HT similarly to 3,4-methylenedioxymethamphetamine. The pyrovalerone cathinones 3,4-methylenedioxypyrovalerone, pyrovalerone, alpha-pyrrolidinovalerophenone, 3,4-methylenedioxy-alpha-pyrrolidinopropiophenone, and 3,4-methylenedioxy-alpha-pyrrolidinobutiophenone potently inhibited the NET and DAT but not the SERT. Naphyrone was the only pyrovalerone that also inhibited the SERT. The pyrovalerone cathinones did not release monoamines. Most of the para-substituted amphetamines exhibited affinity for the 5-HT2A receptor but no relevant activation of the 5-HT2B receptor. All the cathinones exhibited reduced trace amine-associated receptor 1 binding compared with the non-beta-keto-amphetamines. In conclusion, para-substituted amphetamines exhibited enhanced direct and indirect serotonergic agonist properties and are likely associated with more MDMA-like effects. The pharmacological profile of the pyrovalerone cathinones predicts pronounced stimulant effects and high abuse liability. (C) 2015 Elsevier B.V. and ECNP. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative

Karolina E. Kolaczynska, Jan Thomann, Marius C. Hoener, Matthias E. Liechti

Summary: Pyrovalerone cathinones are potent DAT and NET inhibitors with high selectivity, potentially leading to strong psychostimulant effects and high abuse liability.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Medicine, Research & Experimental

Antisense oligonucleotide treatment rescues UBE3A expression and multiple phenotypes of an Angelman syndrome mouse model

Claudia Milazzo, Edwin J. Mientjes, Ilse Wallaard, Soren Vestergaard Rasmussen, Kamille Dumong Erichsen, Tejaswini Kakunuri, A. S. Elise van der Sman, Thomas Kremer, Meghan T. Miller, Marius C. Hoener, Ype Elgersma

Summary: Research findings demonstrate that ASO-induced reactivation of UBE3A in AS mice can lead to positive effects on AS phenotypes, such as restored sensitivity to seizures and improvements in behavior, indicating therapeutic potential.

JCI INSIGHT (2021)

Article Biochemistry & Molecular Biology

TAAR1 Expression in Human Macrophages and Brain Tissue: A Potential Novel Facet of MS Neuroinflammation

David A. Barnes, Dylan A. Galloway, Marius C. Hoener, Mark D. Berry, Craig S. Moore

Summary: The expression of TAAR1 is found to be decreased in MS patients, while its localization and function are altered under different conditions. This suggests a potential important role of TAAR1 in the pathophysiology of MS.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Pharmacology & Pharmacy

Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines

Karolina E. Kolaczynska, Dino Luethi, Daniel Trachsel, Marius C. Hoener, Matthias E. Liechti

Summary: The psychedelic alkaloids, scalines and 3C-scalines, were found to have similar effects to mescaline and could potentially be used as novel therapeutics for psychedelic-assisted therapy. These compounds interacted with various monoamine receptors, with higher affinity observed at 5-HT2A and 5-HT2C receptors.

FRONTIERS IN PHARMACOLOGY (2022)

Article Clinical Neurology

Pharmacological characterization of 3,4-methylenedioxamphetamine (MDA) analogs and two amphetamine-based compounds: N,α-DEPEA and DPIA

Karolina E. Kolaczynska, Paula Ducret, Daniel Trachsel, Marius C. Hoener, Matthias E. Liechti, Dino Luethi

Summary: This article examines the pharmacological properties of MDA analogs and related amphetamine-based compounds, including monoamine uptake inhibition and release, as well as transporter and receptor binding and activation properties. The study finds that some MDA analogs have similar pharmacological profiles to MDMA, while others have more pronounced dopaminergic activity. Further research on the pharmacokinetics and pharmacodynamics of these drugs is needed to better evaluate their risks and therapeutic potential.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2022)

Meeting Abstract Biochemistry & Molecular Biology

Monoamine Receptor and Transporter Interaction Profiles of 4-Alkyl-Substituted 2,5-Dimethoxyamphetamines

Dino Luethi, Deborah Rudin, Marius C. Hoener, Mattias E. Liechti

FASEB JOURNAL (2022)

Meeting Abstract Biochemistry & Molecular Biology

Structure-activity Relation of Halogenated 2,5-Dimethoxyamphetamines Compared to their α-Desmethyl (2C) Analogues

Deborah Rudin, Dino Luethi, Marius C. Hoener, Matthias E. Liechti

FASEB JOURNAL (2022)

Article Biochemistry & Molecular Biology

Effects of acute and chronic administration of trace amine-associated receptor 1 (TAAR1) ligands on in vivo excitability of central monoamine-secreting neurons in rats

Daniil Grinchii, Marius C. Hoener, Talah Khoury, Roman Dekhtiarenko, Reyhaneh Nejati Bervanlou, Daniela Jezova, Eliyahu Dremencov

Summary: Trace amine-associated receptor 1 (TAAR1) has been identified as a potential target for future antidepressant, antipsychotic, and anti-addiction drugs. Studies have shown that TAAR1 agonists can produce antidepressant, antipsychotic, and anti-addiction behavioral effects in rodents and primates, and these effects are associated with the modulation of serotonin (5-HT) and dopamine.

MOLECULAR PSYCHIATRY (2022)

Article Neurosciences

TAAR1 Regulates Purinergic-induced TNF Secretion from Peripheral, But Not CNS-resident, Macrophages

David A. Barnes, Marius C. Hoener, Craig S. Moore, Mark D. Berry

Summary: This study reveals the role of Trace amine-associated receptor 1 (TAAR1) in modulating cytokine secretion and metabolic profiles in peripherally-derived macrophages. It also suggests a potential therapeutic target for inflammatory disorders. However, TAAR1 does not have the same effect in CNS-resident macrophages.

JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2023)

Article Neurosciences

Use of the head-twitch response to investigate the structure-activity relationships of 4-thio-substituted 2,5-dimethoxyphenylalkylamines

Adam L. Halberstadt, Dino Luethi, Marius C. Hoener, Daniel Trachsel, Simon D. Brandt, Matthias E. Liechti

Summary: This study investigated the structure-activity relationships of 4-thio-substituted phenylalkylamines and found that these compounds have psychedelic effects, supporting their classification as psychedelics.

PSYCHOPHARMACOLOGY (2023)

Article Biochemistry & Molecular Biology

Activation of trace amine-associated receptor 1 (TAAR1) transiently reduces alcohol drinking in socially housed mice

Bartosz Adam Frycz, Klaudia Nowicka, Anna Konopka, Marius Christian Hoener, Ewa Bulska, Leszek Kaczmarek, Marzena Stefaniuk

Summary: Alcohol dependence is characterized by abnormal dopamine release in the brain. TAAR1, a receptor that regulates dopamine neurotransmission, may be a target for treating addiction. This study examined the effects of TAAR1 activation on alcohol consumption in mice and found that activation of TAAR1 reduces alcohol drinking and preference. The findings suggest that TAAR1 is a promising target for treating alcohol abuse and relapse.

ADDICTION BIOLOGY (2023)

Review Neurosciences

Translational molecular imaging and drug development in Parkinson's disease

Ahmed Haider, Nehal H. Elghazawy, Alyaa Dawood, Catherine Gebhard, Thomas Wichmann, Wolfgang Sippl, Marius Hoener, Ernest Arenas, Steven H. Liang

Summary: Parkinson's disease (PD) is a progressive neurodegenerative disorder primarily affecting the elderly. PD is characterized by nigrostriatal loss and the formation of misfolded alpha-synuclein protein aggregates. Motor symptoms can be managed with dopaminergic therapy initially, but ultimately become unresponsive. Molecular imaging techniques such as PET and SPECT can be used to study PD.

MOLECULAR NEURODEGENERATION (2023)

Correction Neurosciences

Trace amine-associated receptor 1 agonism promotes wakefulness without impairment of cognition in Cynomolgus macaques (vol 44, pg 1485, 2019)

Anushka V. Goonawardena, Stephen R. Morairty, Ryan Dell, Gabriel A. Orellana, Marius C. Hoener, Tanya L. Wallace, Thomas S. Kilduff

NEUROPSYCHOPHARMACOLOGY (2023)

Article Cell Biology

Secreted retrovirus-like GAG-domain-containing protein PEG10 is regulated by UBE3A and is involved in Angelman syndrome pathophysiology

Nikhil J. Pandya, Congwei Wang, Veronica Costa, Paul Lopatta, Sonja Meier, F. Isabella Zampeta, A. Mattijs Punt, Edwin Mientjes, Philip Grossen, Tania Distler, Manuel Tzouros, Yasmina Marti, Balazs Banfai, Christoph Patsch, Soren Rasmussen, Marius Hoener, Marco Berrera, Thomas Kremer, Tom Dunkley, Martin Ebeling, Ben Distel, Ype Elgersma, Ravi Jagasia

Summary: Angelman syndrome is a neurodevelopmental disorder caused by the loss of maternal UBE3A, and studying neurons derived from patients with AS and neurotypical individuals have revealed the potential involvement of the protein PEG10 in AS pathophysiology. Further research on PEG10 and its interaction with RNA and certain proteins may shed light on the mechanisms underlying this disorder.

CELL REPORTS MEDICINE (2021)

Meeting Abstract Pharmacology & Pharmacy

Trace amine receptor-1 (TA1) as a novel immunomodulatory target in multiple sclerosis

David Barnes, Marius Hoener, Craig Moore, Mark Berry

BRITISH JOURNAL OF PHARMACOLOGY (2021)

Article Clinical Neurology

A posterior-alpha ageing network is differentially associated with antidepressant effects of venlafaxine and rTMS

Hannah Meijs, Helena Voetterl, Alexander T. Sack, Hanneke van Dijk, Bieke De Wilde, Jan Van Hecke, Peter Niemegeers, Evian Gordon, Jurjen J. Luykx, Martijn Arns

Summary: This study used a polygenic score (PGS) and electroencephalography (EEG) data analysis to identify potential predictors for treatment outcomes in major depressive disorder (MDD). The results suggest the existence of a stable EEG network related to antidepressant-response that has potential as a predictor for MDD treatment, particularly in the case of venlafaxine.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2024)